CSL Limited (OTCMKTS:CSLLY) is a global biotechnology company headquartered in Melbourne, Australia. The firm specializes in the development, manufacture and distribution of a broad portfolio of biopharmaceutical products. Through its two primary business units—CSL Behring and Seqirus—CSL focuses on immunoglobulin therapies, coagulation factors and influenza vaccines, serving patients in more than 60 countries worldwide.
CSL Behring is a leading provider of plasma‐derived and recombinant therapies for people with rare and serious diseases. Its product range includes immunoglobulins for immune system support, albumin solutions used in critical care settings, and specialty coagulation factors for hemophilia management. In parallel, Seqirus is one of the world’s largest influenza vaccine companies, offering seasonal and pandemic flu vaccines developed using cell culture, egg-based and adjuvant technologies to help protect public health.
Founded in 1916 as Commonwealth Serum Laboratories to address health challenges in Australia, CSL has grown into an international enterprise with research and manufacturing facilities across North America, Europe and the Asia-Pacific region. The company maintains a network of plasma collection centers and invests heavily in research and development to advance novel therapies and vaccine platforms, including next-generation approaches to more effectively combat infectious diseases.
Under the leadership of Chief Executive Officer Paul Perreault, CSL continues to pursue strategic collaborations and acquisitions aimed at expanding its product pipeline and global reach. The company’s commitment to innovation, quality and patient access underpins its ongoing efforts to address unmet medical needs and to strengthen its position in the competitive biopharmaceutical landscape.
AI Generated. May Contain Errors.
